ReviewImmunologic research2015
Intravenous immunoglobulins (IVIG) in systemic sclerosis: a challenging yet promising future.
Review in Immunologic research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Efficacy and safety of intravenous immunoglobulin therapy in systemic sclerosis: a systematic review.Rheumatology international · 2024Pooled it
- A phase 2 randomized trial of safety and pharmacokinetics of IgPro20 and IgPro10 in patients with diffuse cutaneous systemic sclerosis.Rheumatology (Oxford, England) · 2025Trial
- Recent Advances in Treatment of Systemic Sclerosis and Morphea.American journal of clinical dermatology · 2024Review
- Intravenous immunoglobulins improve skin fibrosis in experimental models of systemic sclerosis.Scientific reports · 2023Article
- Subcutaneous immunoglobulin therapy for refractory skin thickening in rapidly progressive systemic sclerosis: A case report and literature review.Journal of scleroderma and related disorders · 2023Review
- Intravenous Immunoglobulins as Immunomodulators in Autoimmune Diseases and Reproductive Medicine.Antibodies (Basel, Switzerland) · 2023Review
- Low dose intravenous immunoglobulin in addition to cyclophosphamide in systemic sclerosis : Single centre experience.Wiener klinische Wochenschrift · 2021Observational
- Immune Abnormalities in Autism Spectrum Disorder-Could They Hold Promise for Causative Treatment?Molecular neurobiology · 2018Review
- Therapeutic plasma exchange for the treatment of systemic sclerosis: A comprehensive review and analysis.Journal of scleroderma and related disorders · 2018Review
- Intestinal Involvement in Systemic Sclerosis: A Clinical Review.Digestive diseases and sciences · 2018Review
- Immunotherapy of systemic sclerosis.Human vaccines & immunotherapeutics · 2018Article
- The Homophilic Domain - An Immunological Archetype.Frontiers in immunology · 2016Review
- Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.Expert opinion on orphan drugs · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The etiology and pathogenesis of systemic sclerosis are still largely unknown, but a variety of humoral and cellular autoimmune phenomena have been documented. In addition, the rarity of the disease, the broad spectrum of clinical manifestations, and the relevant risk of severe complications as well as the highly variable disease course render its management a major challenge. Some immunomodulatory agents have been used, but no single agent has given a convincing proof of effectiveness, and treatment has remained largely symptomatic through recent years. Novel therapies are currently being tested and may have the potential of modifying the disease process and overall clinical outcome. Efficacy of intravenous immunoglobulins (IVIG) in different regimens (1-2 g/kg of body weight, administered over 2-5 consecutive days) has been described in a limited number of trials and small case series, showing benefits in skin, articular, and lung interstitial disease symptoms. However, studies on IVIG in systemic sclerosis still remain few, and further randomized controlled trials should be undertaken to assess their clinical effectiveness or define the optimal dosage and times of administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.